Truist Securities analyst Greg Renza reiterated a Buy rating and $818.00 price target on Regeneron Pharma (NASDAQ: REGN)

The analyst commented, "This morning, REGN shared topline results from a ph.III study of olatorepatide (ola'; dual GLP-1/GIPR agonist) for the treatment of adults with obesity or who are overweight, conducted by Hansoh (3692.HK, NR) in China. Ola' (QW) demonstrated a 19% in mean weight loss, with statistical significance, from baseline at wk 48, with appreciable tolerability versus the incretin class, in our view, with the average incidence of nausea <10% and vomiting <5%. We look ahead to more detailed data at a medical meeting and are encouraged on the potential of the in-licensed obesity asset, gaining a seat at the table. REGN in-licensed ola' from Hansoh in June 2025 for $80M upfront + $1.93B in developmental, regulatory, and sales milestones + future potential low-double digit royalties. Hansoh maintains rights of ola' in mainland China, Hong Kong, and Macau. With defensibility and strength of the commercial portfolio and small hints of activity, however incremental, on tangible pipeline drivers, we reiterate our Buy rating on REGN shares."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $759.86 yesterday.